End-organ dysfunction and cardiovascular outcomes: the role of the microcirculation

被引:56
作者
Lockhart, Christopher J. [1 ]
Hamilton, Paul K. [1 ]
Quinn, Cathy E. [1 ]
McVeigh, Gary E. [1 ]
机构
[1] Queens Univ Belfast, Sch Med, Dept Therapeut & Pharmacol, Belfast BT9 7BL, Antrim, North Ireland
关键词
cardiovascular disease; end-organ dysfunction; flow-mediated dilation; microcirculation; risk factor; vasculature; FLOW-MEDIATED DILATION; CORONARY-HEART-DISEASE; RETINAL VESSEL DIAMETERS; WHITE-MATTER LESIONS; VASCULAR ENDOTHELIAL DYSFUNCTION; DEPENDENT DIABETES-MELLITUS; NATIONAL-KIDNEY-FOUNDATION; URINARY ALBUMIN EXCRETION; NITRIC-OXIDE MODULATION; RENAL RESISTIVE INDEX;
D O I
10.1042/CS20080069
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Risk factors for cardiovascular disease mediate their effects by altering the structure and function of wall and endothelial components of arterial blood vessels. A pathological change in the microcirculation plays a pivotal role in promoting end-organ dysfunction that not only predisposes to further organ damage, but also increases the risk for future macrovascular events. The microcirculation is recognized as the site where the earliest manifestations of cardiovascular disease, especially inflammatory responses, occur that may play a pivotal role in driving the atherosclerotic process in conduit vessels. Furthermore, the vast surface area of the endothelium compared with conduit vessels means that the vascular effects of endothelial dysfunction or activation will be most apparent in this section of the vasculature. Current techniques providing indices of vascular health focus on large arteries without providing insight into the structure and function of small vessels. Techniques capable of detecting microvascular damage and monitoring the response to therapeutic interventions, especially in vulnerable target organs of interest, may improve risk stratification and represent a valuable surrogate for future cardiovascular outcome.
引用
收藏
页码:175 / 190
页数:16
相关论文
共 159 条
[11]   Relationship between the resistive index and vascular compliance and resistance [J].
Bude, RO ;
Rubin, JM .
RADIOLOGY, 1999, 211 (02) :411-417
[12]   Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes [J].
Caballero, AE ;
Arora, S ;
Saouaf, R ;
Lim, SC ;
Smakowski, P ;
Park, JY ;
King, GL ;
LoGerfo, FW ;
Horton, ES ;
Veves, A .
DIABETES, 1999, 48 (09) :1856-1862
[13]   Medical progress - Coronary microvascular dysfunction [J].
Camici, Paolo G. ;
Crea, Filippo .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :830-840
[14]   Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy [J].
Cecchi, F ;
Olivotto, I ;
Gistri, R ;
Lorenzoni, R ;
Chiriatti, G ;
Camici, PG .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (11) :1027-1035
[15]   Microvascular disease and cardiomyopathy [J].
Cheung, Ning ;
Wong, Tien Yin .
JOURNAL OF CARDIAC FAILURE, 2007, 13 (09) :792-792
[16]   Retinal arteriolar narrowing and left ventricular remodeling - The multi-ethnic study of atherosclerosis [J].
Cheung, Ning ;
Bluemke, David A. ;
Klein, Ronald ;
Sharrett, A. Richey ;
Islam, F. M. Amirul ;
Cotch, Mary Frances ;
Klein, Barbara E. K. ;
Criqui, Michael H. ;
Wong, Tien Yin .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (01) :48-55
[17]   Diabetic retinopathy and the risk of coronary heart disease - The Atherosclerosis Risk in Communities Study [J].
Cheung, Ning ;
Wang, Jie Jin ;
Klein, Ronald ;
Couper, David J. ;
Sharrett, A. Richey ;
Wong, Tien Y. .
DIABETES CARE, 2007, 30 (07) :1742-1746
[18]   Arterial stiffness, vascular disease, and risk of cardiovascular events [J].
Cohn, JN .
CIRCULATION, 2006, 113 (05) :601-603
[19]   Surrogate markers for cardiovascular disease functional markers [J].
Cohn, JN ;
Quyyumi, AA ;
Hollenberg, NK ;
Jamerson, KA .
CIRCULATION, 2004, 109 (25) :31-46
[20]   Mechanisms of target organ damage caused by hypertension: Therapeutic potential [J].
Cohuet, G. ;
Struijker-Boudier, H. .
PHARMACOLOGY & THERAPEUTICS, 2006, 111 (01) :81-98